Charles River Laboratories International (STU:RV6) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Charles River Laboratories International EBITDA Margin % Related Terms
Charles River Laboratories International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International EBITDA Margin % Chart
Charles River Laboratories International Annual Data
STU:RV6 vs RVTY, QGEN, ICLR: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (STU:RV6) has a EBITDA Margin % of 6.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Charles River Laboratories International and its competitors. This is 72% below median its historical median of 22.81. Over the past decade, Charles River Laboratories International's EBITDA Margin % has ranged from 7.22 to 26.28. According to the industry distribution chart, Charles River Laboratories International ranks #96 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 47.3%.
Is Charles River Laboratories International's EBITDA Margin % too high?
Charles River Laboratories International's current EBITDA Margin % of 6.42% is 72% below median its 10-year median of 22.81. Over the past 10 years, this metric has ranged from a low of 7.22 to a high of 26.28. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Charles River Laboratories International's value of 6.42% is 28.4% above this industry median. Based on the distribution chart, Charles River Laboratories International ranks #96 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's EBITDA Margin % compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #96 out of 203 companies for EBITDA Margin %. This puts Charles River Laboratories International in the upper half of its industry. The industry median EBITDA Margin % is 5.00. Charles River Laboratories International's value of 6.42% is 28.4% above this benchmark. Historically, Charles River Laboratories International's own EBITDA Margin % has ranged from 7.22 to 26.28 over the past decade. While the company's 10-year median is 22.81 vs. the industry median of 5.00, Charles River Laboratories International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current EBITDA Margin % of 6.42% is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current EBITDA Margin % is 6.42%, which is 72% below median its own 10-year median of 22.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (STU:RV6) is currently considered Modestly Overvalued. The stock's GF Value™ is €170.09, compared to a current price of €188.50 — trading 10.8% above its estimated fair value. The current EBITDA Margin % is 6.42%, which is 72% below median its 10-year median of 22.81 and 28.4% above the Medical Diagnostics & Research industry median of 5.00. Charles River Laboratories International's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Charles River Laboratories International (STU:RV6), the current EBITDA Margin % is 6.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (STU:RV6) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of €188.50 is trading 10.8% above its estimated GF Value™ of €170.09.
GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.
Key valuation signals for STU:RV6:
EBITDA Margin %: 6.42% (72% below median its 10-year median of 22.81)
GF Value™: €170.09 vs. price of €188.50 (10.8% above fair value)
Industry Position: 28.4% above the Medical Diagnostics & Research median (#96 of 203)
No single metric tells the full story. See the STU:RV6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
68GF Score
Get the complete analysis for STU:RV6
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RV6 has been successfully added to your 
